Introduction {#s1}
============

Biological products are therapeutic options for different diseases. These drugs are molecules with a complex structure, large and often highly specific and are derived from living organisms ([@B48]; [@B64]; [@B4]). Biologic drugs are used to treat various diseases, including conditions that involve the immune system, randomized studies have shown their efficacy for reducing symptoms and improving the quality of life in people undergoing treatment ([@B64]; [@B70]). However, a significant number of patients do not respond, have an inadequate response to initial treatment (primary failure), lose response over time (secondary failure), or may develop adverse effects potentially limiting the therapy ([@B4]). One of these drugs is infliximab (REMICADE^®^), a tumor necrosis factor alpha inhibitor (TNFa) ([@B21]). Infliximab has been approved for the treatment of rheumatoid arthritis (RA), severe psoriasis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis, among other diseases.([@B1]; [@B22]; [@B24]). Efficacy, effectiveness, and safety of this biological drug has been tested in different studies ([@B36]). Hence, infliximab is currently included in the pharmacological petition of the Peruvian Social Security (EsSalud). ([@B54]).

On the other hand, the biosimilar biological products (BBP) are an efficient treatment alternative to the biological reference products (BRP). They usually offering similar effects and lower cost ([@B18]; [@B28]). BBP contains the active component of BRP with similar characteristics in its pharmacological activity, efficacy and safety ([@B25]; [@B28]). The equivalence of BBP has been reported from comparison -- in equal terms - with BRP in various randomized clinical trials ([@B49]; [@B63]), where infliximab is one the most studied drugs ([@B28]). Based on this information, international guidelines for its regulation have been spread and adopted in several countries ([@B26]; [@B55]; [@B62]; [@B69]). The Peruvian health system is fragmented, segmented and inequitable ([@B53]), where around 25% of population are affiliated to EsSalud ([@B41]). The General Directorate of Medicines, Supplies and Drugs (DIGEMID, from Spanish Acronym) as the national health authority, approved the commercialization of some infliximab biosimilars in Peru ([@B42]). Therefore, certain public institutions, supported by the Peruvian Government contracting laws, including the Social Security, have purchased BBP. Currently, in EsSalud there are two kinds of patients: those who will start treatment with Infliximab and those who continue their therapy with Infliximab. In the first group, the use of biosimilar is accepted as valid; however, in the other group, there are certain concerns with respect to the continuation with BBP.

Based on the context described, a decision should be made regarding the continuation with a biosimilar in patients undergoing treatment with original infliximab in EsSalud. Although, there are several definitions on interchangeability, in our manuscript it means a transition from using BRP to BBP ([@B28]; [@B61]). At the moment, there is an interesting debate about interchangeability with active participation of distinct actors from different health care systems; thus, international regulations have been proposed to the use of BBP and the transition from its BRP ([@B49]; [@B62]; [@B15]; [@B45]). Nevertheless, in Peru, and specifically in EsSalud, there is no explicit decree for it. Therefore, the Institute for Health Technology Assessment and Research (IETSI, from Spanish acronym) - as technical entity in EsSalud - must evaluate the best available scientific evidence to inform decision-making in the Peruvian Social Security.

In light of the above mentioned, the aim of our study was to synthesize the best available evidence, calculate a preliminary financial impact, and conduct a technical discussion concerning the interchangeability into biosimilar in patients undergoing treatment with original infliximab for medical conditions approved in EsSalud. Although there are systematic reviews published ([@B14]; [@B15]; [@B39]; [@B23]), our study incorporates two key elements used in the decision-making process for health systems with limited resources: institutional budget and clinical experience. Consequently, our article is a description of this complexity in Peru and shows the use of the best scientific evidence in the real world.

Methods {#s2}
=======

In our manuscript, we describe the three main activities performed in order to inform the decision-making process in EsSalud regarding infliximab interchangeability:

1.  a\) Systematic review based on PRISMA guidelines ([@B44]),

2.  b\) Preliminary financial analysis about the direct impact on institutional purchasing budget of EsSalud, and

3.  c\) Technical meeting with rheumatologists, dermatologists and gastroenterologists for discussing the results from clinical practice perspective.

Systematic Review {#s3}
=================

Clinical Question (PICOS) {#s3_1}
-------------------------

The population(P) was circumscribed to adults with rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease and ankylosing spondylitis undergoing treatment with the original Infliximab. Intervention(I) was to exchange into a biosimilar, and comparison(C) was the continuation with original Infliximab. The outcomes(O) were efficacy and safety. In accordance with current legal regulations in EsSalud, we included only controlled clinical studies(S) in biosimilar drugs approved by DIGEMID for their commercialization in Peru (CTP-13 and SB2).

Search Strategy and Selection of Study {#s3_2}
--------------------------------------

We conducted a search without language restrictions until June 2018. Primary strategy formulation included controlled and free terms according to PICOS question. Studies were restricted to clinical trials in humans of any age, gender or nationality. We searched in: PubMed-MEDLINE, SCOPUS, Web of Science (WOS), Excerpta Medica (EMBASE), Translating Research into Practice (TRIPDATABASE), Database of Abstracts of Reviews of Effects (DARE), Cochrane Central Register of Controlled Trials (CENTRAL), National Institute for Health and Care Excellence (NICE), The Agency for Healthcare Research and Quality (AHRQ), The Scottish Medicines Consortium (SMC), McMaster PLUS, The Canadian Agency for Drugs and Technologies in Health (CADTH), and The Health Systems Evidence (HSE). Primary search strategies for each database are explicitly presented as annexes (A-N) ([**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}). Additionally, we reviewed the list of references. Poster and oral presentations in scientific meetings were not considered.

Article Selection {#s3_3}
-----------------

Records found were collected in an electronic folder using Mendeley^®^ (Elsevier Inc, NY, USA) and we generated a Research Information Systems (RIS) file. Duplicates were removed by automatic and manual methods; then, we exported a new file to Rayyan^®^ (Qatar Computer Research Institute, Doha, Qatar). Two authors (LHS and LLS) completed a blind and independent selection based on abstract and title, third author (EMH) had diriment decision. Then, two authors (LH-S and LL-S) selected articles in full-text evaluation with third author as diriment (EM-H). Afterward, two evaluators (LHS and LLS) codified the articles and uploaded them in Google Drive^®^ folder (Google Inc, CA, USA).

Risk of Bias Assessment {#s3_4}
-----------------------

Two authors (LHS and LLS) acted upon blind and independent appraisal of clinical trials using the Cochrane Collaboration tool([@B29]). Disagreements were resolved by consensus and diriment participation (EMH).

Statistical Synthesis {#s3_5}
---------------------

Although a meta-analysis was initially proposed, it was not performed due to clinical and methodological heterogeneity.

Preliminary Financial Analysis {#s3_6}
------------------------------

We implemented an analysis about the impact of biosimilar introduction in the institutional purchasing budget based on the official reports of EsSalud and Electronic Government Procurement System of Peru (SEACE, from Spanish Acronym).

Technical Meeting {#s3_7}
-----------------

We held several face-to-face meetings to present and discuss the results of the systematic review and financial analysis. A group of rheumatologists, dermatologists and gastroenterologists working in hospitals of EsSalud in Lima, participated in these reunions.

Results {#s4}
=======

Selection and Characteristics of Studies {#s4_1}
----------------------------------------

We identified a total of 1136 records in the primary search, from which we removed 357 duplicates. From 799 screened records, we excluded 765 in title and abstract evaluation. Then, we appraised 14 full-text documents, and included five clinical trials for risk of bias assessment and data extraction ([**Figure 1**](#f1){ref-type="fig"}).

![Flow diagram of Study Selection according PRISMA guidelines.](fphar-10-01010-g001){#f1}

We found five controlled studies, that corresponded to five publications, which evaluated the interchangeability between Infliximab and its PBB. Only one assessed SB2 biosimilar ([@B57]), and the four remaining studies evaluated biosimilar CTP-13. Two publications were double-blind Randomized controlled studies (RCT), while the remaining three were open-label continuation of clinical trials that initially compared the PBR with PBB. Three studies focused specifically on patients with rheumatoid arthritis, one in ankylosing spondylitis and another, in addition to these two diseases, included Crohn's disease, ulcerative colitis, psoriatic arthritis and chronic plaque psoriasis. In [**Table 1**](#T1){ref-type="table"} we present the general characteristics of trials included.

###### 

Characteristics of primary studies included in the analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)                     Design (Founding)                                                             Population                                                                                                                   Countries            Comparison (Pre/post exchange)\*   Average time (Pre/post exchange)   Conclusion
  --------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- -------------------- ---------------------------------- ---------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [***Biosimilar: SB2***]{.ul}                                                                                                                                                                                                                                                                                                            

  [@B57]                            Randomized double-blind phase 3 trial(Samsung Bioepis Co Ltd.)                Rheumatoid arthritis                                                                                                         Bulgaria\            INF/INF\                           (54/46 weeks)                      The efficacy, safety and immunogenicity profiles were similar between the groups: INF/SB2,INF/INF and SB2/SB2.No emergent treatment or clinically relevant problems were observed after the change from INF to SB2
                                                                                                                                                                                                                                               Colombia\            (n=101)\                                                              
                                                                                                                                                                                                                                               Czech Republic\      SB2/SB2\                                                              
                                                                                                                                                                                                                                               Hungary\             (n=201)\                                                              
                                                                                                                                                                                                                                               Republic of Korea\   INF/SB2\                                                              
                                                                                                                                                                                                                                               Lithuania\           (n=92)                                                                
                                                                                                                                                                                                                                               Mexico\                                                                                    
                                                                                                                                                                                                                                               Poland\                                                                                    
                                                                                                                                                                                                                                               Ukraine\                                                                                   
                                                                                                                                                                                                                                               UK                                                                                         

  [***Biosimilar: CT-P13***]{.ul}                                                                                                                                                                                                                                                                                                         

  [@B32]                            Randomized double-blind non-inferiority phase 4 trial(Government of Norway)   Crohn's disease, ulcerative colitis, rheumatoid arthritis, spondylarthritis, psoriatic arthritis, chronic plaque psoriasis   Norway               CT-P13/ CT-P13\                    (26/52 weeks)\*\*                  The change from INF to CT-P13 showed no inferiority to the continuous treatment with INF in terms of safety and immunogenicity for all the diseases studied.However, there was not enough statistical power to demonstrate non-inferiority for each disease.
                                                                                                                                                                                                                                                                    (n=241)\                                                              
                                                                                                                                                                                                                                                                    INF/CT-P13\                                                           
                                                                                                                                                                                                                                                                    (n=241)                                                               

  [@B59]                            Open label extension of phase 2 trial(Celltrion Inc)                          Rheumatoid arthritis                                                                                                         Japan                CT-P13/ CT-P13\                    (52/72 weeks)\*\*\*                CT-P13 was well tolerated with persistent efficacy for both groups. Likewise, stable clinical efficacy was shown in patients with RA.
                                                                                                                                                                                                                                                                    (n=38)\                                                               
                                                                                                                                                                                                                                                                    INF/CT-P13\                                                           
                                                                                                                                                                                                                                                                    (n=33)                                                                

  [@B68]                            Open label extension of the phase 3-PLANETRA trial(Celltrion Inc)             Rheumatoid arthritis                                                                                                         Bosnia\              CT-P13/ CT-P13\                    (54/48 weeks)                      The efficacy and tolerability observed was similar between patients who were switched from INF to CTP-13 and those who had a long-term treatment with CT-P13 for two years.
                                                                                                                                                                                                                                               Bulgaria\            (n=158)\                                                              
                                                                                                                                                                                                                                               Chile\               INF/CT-P13\                                                           
                                                                                                                                                                                                                                               Colombia\            (n=144)                                                               
                                                                                                                                                                                                                                               Italy\                                                                                     
                                                                                                                                                                                                                                               Latvia\                                                                                    
                                                                                                                                                                                                                                               Lithuania\                                                                                 
                                                                                                                                                                                                                                               Mexico\                                                                                    
                                                                                                                                                                                                                                               Peru\                                                                                      
                                                                                                                                                                                                                                               Poland\                                                                                    
                                                                                                                                                                                                                                               Philippines\                                                                               
                                                                                                                                                                                                                                               Romania\                                                                                   
                                                                                                                                                                                                                                               Slovakia\                                                                                  
                                                                                                                                                                                                                                               Spain\                                                                                     
                                                                                                                                                                                                                                               UK\                                                                                        
                                                                                                                                                                                                                                               Ukraine                                                                                    

  [@B47]                            Open-label extension of a phase 3-PLANETAS trial(Celltrion Inc)               Ankylosing spondylitis                                                                                                       Bulgaria\            CT-P13/ CT-P13\                    (54/48 weeks)                      The exchange from the original biological reference product into biosimilar is possible without negative effects on safety and efficacy in patients with ankylosing spondylitis.
                                                                                                                                                                                                                                               Chile\               (n=388)\                                                              
                                                                                                                                                                                                                                               Colombia\            INF/CT-P13\                                                           
                                                                                                                                                                                                                                               Republic of Korea\   (n=86)                                                                
                                                                                                                                                                                                                                               Latvia\                                                                                    
                                                                                                                                                                                                                                               Mexico\                                                                                    
                                                                                                                                                                                                                                               Poland\                                                                                    
                                                                                                                                                                                                                                               Portugal\                                                                                  
                                                                                                                                                                                                                                               Spain\                                                                                     
                                                                                                                                                                                                                                               Ukraine                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* The number of patients corresponds to exchanging started time.

\*\* Randomization was applied in patients who already had treatment with the original infliximab drug for a minimum of 6 months.

\*\*\* The initial phase of treatment ended at 54 weeks. The first dose of the second stage started eight weeks later in week 62.

Only two articles respond directly to the PICO question, since they evaluated the exchange of the original Infliximab to the biosimilar compared to the maintenance of the original biotherapy: [@B57] and [@B32], who tested SB2 and CTP-13, respectively. In both cases, they did not find statistical differences in efficacy or safety between maintenance and exchanging groups.

The other three publications did not respond directly to PICOS question. These studies did not contain primary safety or efficacy data in a blind setting. Instead, they provided complementary information with the purpose of expanding the perspective of clinical use in potential EsSalud scenarios. Those publications reported the evaluation of open-label continuation of primary clinical trials: [@B59], [@B68], and [@B47]. In these publications no differences were found in efficacy or safety between patients who switched from original infliximab to biosimilar (INF/CTP-13), and maintained biosimilar treatment (CTP-13/CTP-13).

Risk of Bias {#s4_2}
------------

In [**Table 2**](#T2){ref-type="table"}, we show the appraisal for each study included. Trials with direct response to PICOS question had lower risk of bias, mainly due to randomization and blinding.

###### 

Risk of bias assessment in each study according Cochrane Collaboration Tool.

  Author (Year)   Selection Bias   Performance bias   Detection bias   Attrition bias   Reporting bias   Others   
  --------------- ---------------- ------------------ ---------------- ---------------- ---------------- -------- -------
  [@B57]\*        *Low*            *Low*              *Low*            *Low*            *Low*            *Low*    *Low*
  [@B32]\*        *Low*            *Low*              *Low*            *Low*            *Low*            *Low*    *Low*
  [@B59]          *High*           *High*             *High*           *High*           *Low*            *Low*    *Low*
  [@B68]          *High*           *High*             *High*           *High*           *Low*            *Low*    *Low*
  [@B47]          *High*           *High*             *High*           *High*           *Low*            *Low*    *Low*

\* These articles respond directly PICOs question.

Description of Evidence {#s4_3}
-----------------------

We briefly described efficacy and safety outcomes for each study: one for SB2 and four for CTP-13. We describe efficacy and safety outcomes.

### Biosimilar SB2 {#s4_3_1}

[@B57] "**Safety, Immunogenicity And Efficacy After Switching From Reference Infliximab To Biosimilar SB2 Compared With Continuing Reference Infliximab And SB2 In Patients With Rheumatoid Arthritis: Results Of A Randomized, Double-Blind, Phase III Transition Study.**" **Annals Of The Rheumatic Diseases; 7:234-40**.

A randomized, double-blind, phase 3 clinical study was carried out in people with rheumatoid arthritis. This study had two initial groups. Patients were randomized into two groups for 52 weeks: 293 were treated with Infliximab (INF) and 292 received biosimilar (SB2). Then, a new randomization was performed, INF group was divided into a maintenance group (INF/INF n=101) or exchanging group (INF/SB2 n=94). Meanwhile, the group initially assigned to SB2 continued with biosimilar (SB2/SB2 n=201). Efficacy, safety and immunogenicity profiles were not different among the groups up to week 78.

Efficacy {#s4_4}
--------

The major findings of this study are presented in [**Table 3A**](#T3A){ref-type="table"}. We describe the findings according the clinical scale used.

###### 

Efficacy outcomes in patients with rheumatoid arthritis.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)   Time                         Groups (patients allocated)   ACR20\*\         ACR50\           ACR70\           DAS28\                EULAR\
                                                                             n(%)             n(%)             n(%)             (media±ds)            n (%)
  --------------- ---------------------------- ----------------------------- ---------------- ---------------- ---------------- --------------------- ------------------------------------------------
  [@B57]          [Exchange:]{.ul}\            INF/INF\                      *[End]{.ul}:*\   *[End]{.ul}:*\   *[End]{.ul}:*\   *[Baseline]{.ul}:*\   *[End]{.ul}*\
                  Week 54\                     (n=101)                       68.8%            47.3%            *31.2%*          4.1±1.5\              *(93 patients):*\
                  [End:]{.ul}\                                                                                                  *[End:]{.ul}\*\**     *No response: 14 (15.1%)Moderate: 47 (50.5%)*\
                  Week 78                                                                                                                             *Good: 32 (34.4%)*

                                               INF/SB2\                      *[End]{.ul}:*\   *[End]{.ul}:*\   *[End]{.ul}:*\   *[Baseline]{.ul}:*\   *[End]{.ul}*\
                                               (n=94)                        63.5%            *37.6%*          *22.4%*          3.9±1.3\              *(85 patients):*\
                                                                                                                                *[End:]{.ul}\*\*:*    No response: 13 (15.3%)Moderate: 44 (51.8%)\
                                                                                                                                                      Good: 28 (32.9%)

                                               SB2/SB2\                      *[End]{.ul}:*\   *[End]{.ul}:*\   *[End]{.ul}:*\   *[Baseline]{.ul}:*\   *[End]{.ul}*\
                                               (n=94)                        68.3%            40.6%            25.6%            4.0±1.4\              *(180 patients):*\
                                                                                                                                *[End:]{.ul}\*\*:*    No response: 23 (12.8%)\
                                                                                                                                                      Moderate: 93 (51.7%)\
                                                                                                                                                      Good: 64 (35.6%)

                  *[Estimated p-value]{.ul}*   *p=0.7316*                    *p=0.3249*       *p=0.3071*       *NA*             *P=0.8074\*\*\**      

  [@B59]          [Exchange:]{.ul}\            CT-P13/CTP-13\                *[End]{.ul}:*\   *[End]{.ul}:*\   *[End]{.ul}:*\   *[Baseline]{.ul}:*\   *[End]{.ul}:*\
                  Week 62\                     n=38                          29(78.4%)        *26* (70.3%)     20(54.1%)        -2.66 ± 1.57\         Moderate or Good:\
                  [End:]{.ul}\                                                                                                  *[End]{.ul}:*\        31(83.8%)
                  Week 167                                                                                                      -2.78 ± 1.59          

                                               INF/CTP-13\                   *[End]{.ul}:*\   *[End]{.ul}:*\   *[End]{.ul}:*\   *[Baseline]{.ul}:*\   *[End]{.ul}:*\
                                               n=33                          62.5%)           17(53.1%)        *13* (40.6%)     -2,01 ± 1.33\         Moderate or Good:\
                                                                                                                                *[End]{.ul}*\         22 (68.8%)
                                                                                                                                -2,03 ± 1.73          

                  *[Estimated p-value]{.ul}*   *P=0.1535*                    *P=0.14*         *P=0.26*         *P=0.612*        *P=0.1498\*\*\**      

  [@B68]          [Exchange:]{.ul}\            CT-P13/CTP-13\                *[End]{.ul}:*\   *[End]{.ul}:*\   *[End]{.ul}:*\   *[Baseline]{.ul}:*\   *[End]{.ul}:*\
                  Week 54\                     n=168                         117 (74.1%)      78 (49.4%)       39(24.7%)        -2,40±1.27\           No response: 15 (9.9%)Moderate: 80 (52.6%)\
                  [End:]{.ul}\                                                                                                  *[End]{.ul}:*\        Good: 43 (28.3%)
                  Week 102                                                                                                      -2.40 ± 1.42          

                                               INF/CTP-13\                   *[End]{.ul}:*\   *[End]{.ul}:*\   *[End]{.ul}:*\   *[Baseline]{.ul}:*\   *[End:]{.ul}*\
                                               n=144                         111(77.1%)       78 (54.2%)       *38 (*26.4%)     -2.37±1.22\           No response: 12 (8.5%)\
                                                                                                                                *[End:]{.ul}*\        Moderate: 69 (48.6%)\
                                                                                                                                -2,48±1.43            Good: 46 (32.4%)

                  *[Estimated p-value]{.ul}*   *p=0.54*                      *p=0.40*         *p=0.7341*       *p=0.99*         *p=0.669\*\*\**       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACR20, ACR50 y ACR70: Improvement in 20%, 50% and 70% according to the American College of Rheumatology criteria.

DAS28, Score of activity of the disease in 28 joints with reactive protein C (PCR).

EULAR, European League against Rheumatism.

\*Jorgensen et al. study included patients with rheumatoid arthritis, however, the random assignment and the sample calculation were for all pathologies. Because it was a subgroup analysis, no results were reported for RA in this table. Baseline corresponds to time of exchanging.

\*\*No differences were founded between the DAS28 indices for each group, no point values were reported at the end of follow-up. The article did not report any differences using graphic methods.

\*\*\*Comparison for moderate or good classification.

###### 

Efficacy findings in clinical trials in patients with ankylosing spondylitis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)    Start / end time             Groups\                      ASAS20 n(%)                  ASAS40 n(%)                  ASAS PR n(%)                 BASDAI (mean)        BASFI (mean)         ASDAS Global Score (mean)   BASMI (mean)
                                                (Patients allocated)                                                                                                                                                                      
  ---------------- ---------------------------- ---------------------------- ---------------------------- ---------------------------- ---------------------------- -------------------- -------------------- --------------------------- -------------------
  [@B47]           *[Exchange]{.ul}:* Week 54   CT-P13/CT-P13\               *[End]{.ul}:* 67/83 (80.7)   *[End]{.ul}:* 53/83 (63.9)   *[End]{.ul}:* 16/83 (19.3)   *[End]{.ul}:* 3.19   *[End]{.ul}:* 3.24   *[End]{.ul}:* 1.86          *[End]{.ul}:* 2.4
                                                (n=88)                                                                                                                                                                                    

  *[End]{.ul}:*\   INF/CT-P13\                  *[End]{.ul}:* 60/78 (76.9)   *[End]{.ul}:* 48/78 (61.5)   *[End]{.ul}:* 18/78 (23.1)   *[End]{.ul}:* 3.23           *[End]{.ul}:* 3.25   *[End]{.ul}: 1.97*   *[End]{.ul}:* 2.6           
  Week 102         (n=86)                                                                                                                                                                                                                 

                   *Estimated p value*          *[0.506]{.ul}*               *[0.672]{.ul}*               *[0.275]{.ul}*               [NS\*]{.ul}                  [NS\*]{.ul}          [NS\*]{.ul}          [NS\*]{.ul}                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*ASAS*, The Assessment of Spondylarthritis International Society; *PR*, Partial Remission; *BASDAI*, The Bath Ankylosing Spondylitis Disease Activity Index; *BASFI*, Bath Ankylosing Spondylitis Functional Index; *ASDAS*, Ankylosing Spondylitis Disease Activity Score; *BASMI*, Bath Ankylosing Spondylitis Metrology Index; *ASDAS*, Ankylosing Spondylitis Disease Activity Score.

\* Standard deviation was not reported. Authors only compared graphically.

### American College Of Rheumatology (ACR20, ACR50 And ACR70) {#s4_4_1}

Authors found that the percentage of patients who showed a 20% improvement (ACR20) at week 78 of follow-up was not statistically different between the three groups: INF/INF (68.8%), SB2/SB2 (65.7%) and INF/SB2 (63.5%) (p-value:0.7316). Also, there was no statistically significant difference between groups in the proportion of patients with 50% improvement (ACR50) (p-value:0.3249). Moreover, in 70% improvement (ACR70), no significant differences were found in (p-value: 0.3071): INF/INF group (31.2%), SB2/SB2 (25.6%) and INF/SB2 (22.4%).

### European League Against Rheumatology Score (EULAR) {#s4_4_2}

EULAR response criteria scores were measured at week 78, no statistically significant differences were observed. Good or moderate responses were 84.9% in INF/INF group, 87.3% in SB2/SB2 group and 84.7% in INF/SB2 group (p-value: 0.8074). Regarding the proportion of patients with good response, there was no significant difference between groups: INF/INF (34.4%), SB2/SB2 (35.6%) and INF/SB2 (32.9%) (p= 0.8740).

### Diseases Activity Score 28 (DAS28), Simple Disease Activity Index (SDAI) And Clinical Diseases Activity Index (CDAI) {#s4_4_3}

These three instruments were used to measure the activity of the disease and there were no significant statistical differences between randomized groups. DAS28 values were (mean±sd): INF/INF (4,1±1,5), SB2/SB2 (4,0±1,4), y INF/SB2 (3,9±1,3). SDAI score in each group were: INF/INF (15,2±12,0), SB2/SB2 (initial 14,6±12,2), and INF/SB2 (13,2±10,0). Regarding CDAI, patients obtained similar scores: INF/INF (15,2±12,0), SB2/SB2 (initial 14,6±12,2), and INF/SB2 (13,2±10,0). No point values were reported at the end of the follow-up at week 78; authors showed graphically the evolution of the scores during the post interchange period, there is no difference between the three groups evaluated ([**Table 3A**](#T3A){ref-type="table"}).

Safety {#s4_5}
------

### Adverse Events {#s4_5_1}

No differences were observed in the frequency of adverse events (AE) among the three post-exchange groups: Specifically, for any AE were: INF/INF (35,6%), SB2/SB2 (40,3%), and INF/SB2 (36,2%) of patients presenting any AE (p=0.546). Regarding serious AE post-exchange, frequencies were: 6.4% in INF/SB2, 3% in INF/INF and 3.5% in SB2/SB2 (p=0.456). Similarly, no differences were found in the frequency of discontinuation due to AE (p=0.625) ([**Table 3E**](#T3E){ref-type="table"}).

### Immunogenicity {#s4_5_2}

Post-exchange immunogenicity levels were very similar among groups: INF/INF (14.9%), SB2/SB2 (14.1%) and INF/SB2 (14.6%) (p=0.98) (p=0.98) ([**Table 3E**](#T3E){ref-type="table"}).

### Biosimilar CTP-13 {#s4_5_3}

[@B32]. **"Switching from Originator Infliximab to Biosimilar CT-P13 Compared with Maintained Treatment with Originator Infliximab (NOR-SWITCH): A 52-Week, Randomized, Double-Blind, Non-Inferiority Trial." Lancet 389 (10086): 2304--16** ([@B32]).

The authors conducted a phase 4, randomized double-blind non-inferiority trial. Patients with Crohn's disease, ulcerative colitis, rheumatoid arthritis, spondylarthrosis, psoriatic arthritis and chronic plaque psoriasis receiving original infliximab were enrolled and randomized in two arms:: maintenance group with the original biological component (INF/INF), and exchanging group from the original biological into its biosimilar (INF/CT-P13). The exchange group showed non-inferiority to the ongoing treatment with INF on efficacy and safety for all diseases investigated. However, there was not enough statistical power to demonstrate the non-inferiority for each disease studied. This research was financed by the Norwegian Government.

Efficacy {#s4_6}
--------

Different measurements were used according to clinical population studied. Authors define two main types of variables: a) *categorical (state)*: percentage of patients with a specified condition (deterioration or remission) based on clinical scales, and b) *numerical (change)*: any variation in the score of clinical scales at the end of the follow-up with respect to the baseline (exchange time).

### Deterioriation During Follow-Up {#s4_6_1}

This was the primary outcome for all patients based on specific clinical scales for each of the six diseases studied. In the ITT analysis, frequency of deterioration in all diseases were 22.4% in the INF/INF group, and a 26.3% in the INF/CTP-13 group (p=0.3259). Although the frequency of decline of the six diseases was defined, there was not enough statistical power to test non-inferiority of each disease; thus, we only report the frequencies for exploratory purposes ([**Table 3C**](#T3C){ref-type="table"}).

###### 

Frequency of deterioration and remission during follow-up in patients with Crohn's disease, ulcerative colitis, spondylarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                        Worsening during follow-up   Remission during follow-up                                                                                                                       
  --------------------- ---------------------------- ---------------------------- ------------ -------------- ------------- ------------- -------------- -------------- ------------- --------------- -------------
  [@B32]                *[Start:]{.ul}*\             INF/INF                      241          54 (22.4%)     11(28.2%)     7 (50%)       2 (11.1%)      17 (37.8%)     14 (17.9%)    3 (6.4%)        145 (60.2%)
                        Week 0                                                                                                                                                                        

  *[End:]{.ul}*\        INF/CT-P13                   240                          63 (26.3%)   *10 (26.3%)*   *8 (50.0%)*   *2 (11.8%)*   *14 (30.4%)*   *24 (31.2%)*   *5 (10.9%)*   *146 (60.8%)*   
  Week 52                                                                                                                                                                                             

  *Estimated p-value*   p=0.3259                     NE                           NE           NE             NE            NE            NE             p=0.8810                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NE, Not estimated due to the low statistical power.

### Remission During Follow-Up {#s4_6_2}

Approximately 60% of patients in each group achieved remission (p=0.8810) ([**Table 3C**](#T3C){ref-type="table"}). There was not enough statistical power to evaluate the non-inferiority for each disease.

### Quality of Life: SF36 and EQ5D {#s4_6_3}

Health-related quality of life (QoL) for all diseases were assessed using SF36 and EQ5D; two validated and widely used instruments. In the first group, statistically significant differences during the follow-up period regarding physical limitations (p=0.0069) and emotional limitations were found (p=0.026); with a greater average of deterioration (decrease in score) in the maintenance group (-0.4) and exchange group (-1.1). There were not statistical differences in the others components. Meanwhile, there were different changes on the clinical global impressions scale of EQ5D in both groups (p=0.999) ([**Table 3D**](#T3D){ref-type="table"}).

###### 

Quality of life in patients with Crohn's disease, ulcerative colitis, spondylarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis (SF36 and EQ5D).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Year)   Time                        Groups\                SF-36 FF              SF-36 LRF             SF-36 Pain            SF-36 SG              SF-36 BE              SF-36 LRE             SF-36\                SF-36\                SF-36 RCF             SF-36 RCM             EQ 5D
                                              (patients allocated)                                                                                                                                       FS                    EF                                                                
  --------------- --------------------------- ---------------------- --------------------- --------------------- --------------------- --------------------- --------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
  [@B32]          *[Exchange:]{.ul}* Week 0   INF/INF\               *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\
                                              (n=241)                50.6\                 45.6\                 47.2\                 43.5\                 50.0\                 48.8\                 48.0\                 47.1\                 46.4\                 49.1\                 0.8\
                                                                     (11.3)\               (11.6)\               (8.5)\                (10.2)\               (9.8)\                (10.8)\               (10.5)\               (10.4)\               (10.1)\               (10.7)\               (0.2)\
                                                                     *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*--1.9\   *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\
                                                                     --1.2\                --1.1\                --0.7\                --1.1\                --1.3\                --0.5\                --0.2\                (8.5)                 --1.2\                --0.7\                0.0\
                                                                     (7.0)                 (11.2)                (7.3)                 (7.3)                 (7.8)                 (12.2)                (9.4)                                       (6.9)                 (8.9)                 (0.2)

                  *[End:]{.ul}* Week 52       INF/CT-P13\            *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\   *[Baseline:]{.ul}*\
                                              (n=240)                50.5\                 46.9\                 47.8\                 44.5\                 50.9\                 50.0\                 48.6\                 46.9\                 46.8\                 50.3\                 0.8\
                                                                     (10.9)\               (11.3)\               (9.5)\                (10.2)\               (8.9)\                (10.4)\               (9.5)\                (10.2)\               (10.3)\               (9.3)\                (0.2)\
                                                                     *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\        *[End:]{.ul}*\
                                                                     0\                    --0.4\                --0.5\                --1.1\                --0.7\                --2.4\                --0.6\                0.5\                  0.2\                  --1.3\                0.0\
                                                                     (6.3)                 (9.4)                 (7.7)                 (7.1)                 (7.8)                 (10.5)                (10.4)                (8.3)                 (6.6)                 (8.9)                 (0.2)

                                              *Estimated p-value*    0.103                 0.0069                0.4096                0.6677                0.999                 0.026                 0.1183                0.7129                0.4921                *0.999*               *0.999*
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SF-36, 36-Item Short Form Health Survey; FF, Physical functioning; LRF, Limitation of physical roles; SG, General Health; BE, Emotional wellbeing; LRE, Limitation of emotional roles; FS, Social Functioning; EF, Energy or Fatigue; RCF, Physical component summary; RCM, Mental component summary; Baseline, exchanging time; End, Conclusion of follow-up.

Safety {#s4_7}
------

There were no statistically significant differences between patients of two groups in safety variables.

### Adverse Events {#s4_7_1}

Frequencies of serious AE were 10% in maintenance patients and 9% in exchanging group. Discontinuation due to AE was 4% and 3%, respectively.

### Immunogenecity {#s4_7_2}

Frequency of patients with post transition ADA were: 7% (INF/INF) and 8% (INF/CTP-13) ([**Table 3E**](#T3E){ref-type="table"}).

###### 

Safety outcomes in all primary studies included.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author\      Conditions                                                                                                                   Exchanging Time              Intervention Groups                                                   Patients allocated           Immunogenicity (ADA)                                                        Patients with adverse events (post exchange)
  (Year)                                                                                                                                                                                                                                                                                                                                                
  ------------ ---------------------------------------------------------------------------------------------------------------------------- ---------------------------- --------------------------------------------------------------------- ---------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------------------
  [@B57]       Rheumatoid arthritis                                                                                                         [Exchange:]{.ul}\            INF/INF                                                               101                          *[Post-transition:]{.ul}*\                                                  Any AE: 36(35.6%)Serious AE: 3 (3%)Discontinuation due to AE: 1 (1%)
                                                                                                                                            Week 54\                                                                                                                        *14.9%*                                                                     
                                                                                                                                            [End:]{.ul}\                                                                                                                                                                                                
                                                                                                                                            Week 78                                                                                                                                                                                                     

                                                                                                                                            SB2/SB2                      201                                                                   *[Post-transition:]{.ul}*\   Any AE:81(40.3%)Serious AE: 7(3.5%)Discontinuation due to AE: 3 (1.5%)      
                                                                                                                                                                                                                                               *14.1%*                                                                                                  

                                                                                                                                            INF/SB2                      94                                                                    *[Post-transition:]{.ul}*\   Any AE: 34(36. 2%)Serious AE: 6 (6.4%)Discontinuation due to AE: 3 (3.2%)   
                                                                                                                                                                                                                                               *14.6%*                                                                                                  

                                                                                                                                            *Estimated p-value*                                                                                *p=0.98*                                                                                                 

  [@B32]\*     Crohn\'s disease. Ulcerative colitis.Rheumatoid arthritis. Spondylarthritis. Psoriatic arthritis. Chronic plaque psoriasis   [Exchange:]{.ul}\            INF/INF                                                               241                          *[Post-transition:]{.ul}*\                                                  Any AE: 168 (70%)Serious AE: 24 (10%)Discontinuation due to AE: 9(4%)
                                                                                                                                            Week 0\                                                                                                                         17 (7.1%)                                                                   
                                                                                                                                            [End:]{.ul}\                                                                                                                                                                                                
                                                                                                                                            Week 52                                                                                                                                                                                                     

  INF/CT-P13   *240*                                                                                                                        *[Post-transition:]{.ul}*\   Any AE: 164 (68%)Serious AE: 21(9%)Discontinuation due to AE: 8(3%)                                                                                                            
                                                                                                                                            19 (7.9%)                                                                                                                                                                                                   

                                                                                                                                            *Estimated p-value*                                                                                0.911                                                                                                    

  [@B59]\*     Rheumatoid arthritis                                                                                                         [Exchange:]{.ul}\            CT-P13/CT-P13                                                         38                           *[Post-transition:]{.ul}*\                                                  Any AE: 34(89. 5%)Serious AE: 2(5.3%)Discontinuation due to AE: 4(10.5%)
                                                                                                                                            Week 54\                                                                                                                        *4 (10.6%)*                                                                 
                                                                                                                                            [End:]{.ul}\                                                                                                                                                                                                
                                                                                                                                            Week 167                                                                                                                                                                                                    

                                                                                                                                                                         INF/CT-P13                                                            33                           *[Post-transition:]{.ul}*\                                                  Any AE: 29 (87.9%)Serious AE: 4 (12.1%)Discontinuation due to AE: 8 (24.2%)
                                                                                                                                                                                                                                                                            *4 (12.1%)*                                                                 

                                                                                                                                            *Estimated p-value*                                                                                *0.901*                                                                                                  

  [@B68]       Rheumatoid arthritis                                                                                                         [Exchange:]{.ul}\            CT-P13/CT-P13                                                         158                          *[Post-transition:]{.ul}*\                                                  Any AE: 85 (53.8%) Serious AE: 12(7.5%)Discontinuation due to AE: 16 (10.1%)
                                                                                                                                            Week 54\                                                                                                                        64(40.5%)                                                                   
                                                                                                                                            [End:]{.ul}\                                                                                                                                                                                                
                                                                                                                                            Week 102                                                                                                                                                                                                    

                                                                                                                                                                         INF/CT-P13                                                            144                          *[Post-transition:]{.ul}*\                                                  Any AE: 77 (53.5%) Serious AE: 13(9.0%)Discontinuation due to AE: 8 (5.6%)
                                                                                                                                                                                                                                                                            64 (44.4%)                                                                  

                                                                                                                                            *Estimated p-value*                                                                                0.48                                                                                                     

  [@B47]       Ankylosing spondylitis                                                                                                       [Exchange:]{.ul}\            CT-P13/CT-P13                                                         88                           *[Post-transition:]{.ul}*\                                                  Any AE: 44 (50%) Serious AE: 4 (4.5%)Discontinuation due to AE: 3 (3.3%)
                                                                                                                                            Week 54\                                                                                                                        21 (23.3%)                                                                  
                                                                                                                                            [End:]{.ul}\                                                                                                                                                                                                
                                                                                                                                            Week 102                                                                                                                                                                                                    

                                                                                                                                                                         INF/CT-P13                                                            86                           *[Post-transition:]{.ul}*\                                                  Any AE: 60 (69.7%)Serious AE: 4 (4.6%)Discontinuation due to AE: 4 (4.6%)
                                                                                                                                                                                                                                                                            23 (27.4%)                                                                  

                                                                                                                                            *Estimated p-value*                                                                                                             0.60                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADA, Anti-drug antibody; NR, Not reported; EA, Adverse Events. Primary outcome was cumulative incidence of AE.

[@B59]. **"Safety and Efficacy of CT-P13 in Japanese Patients with Rheumatoid Arthritis in an Extension Phase or after Switching from Infliximab." Modern Rheumatology 27 (2): 237--45** ([@B59]).

This open label study, RA patients were randomized in two arms: INF/CTP-13 and CTP-13/CTP-13. There were no statistical differences in efficacy and safety assessed by clinical scales.

Efficacy {#s4_8}
--------

### ACR20, ACR50 and ACR70 {#s4_8_1}

No differences were found in frequency of patients who improved in the three categories proposed by the American College of Rheumatology: ACR20%, ACR50% and ACR70%. In CTP-13/CTP-13 (78.4%, 70.3% and 54.1%) and INF/CTP-13 (62.5%, 53.1% and 40.6%), respectively ([**Table 3A**](#T3A){ref-type="table"}).

### DAS28 {#s4_8_2}

There were also no differences in the average scores at the end of the follow-up between maintenance group (2.78) and exchange group (2.03) (p=0.612) ([**Table 3A**](#T3A){ref-type="table"}).

### EULAR {#s4_8_3}

Frequency of good or moderate response after the follow-up period did not show significant statistical difference between the two groups: 83% in maintenance patients and 68.8% in exchanging people ([**Table 3A**](#T3A){ref-type="table"}).

Safety {#s4_9}
------

### Adverse Events {#s4_9_1}

In maintenance group, 5.3% of patients had serious AE and 10.5% discontinuing the prescription due to AE. Meanwhile, in CTP-13 exchanging group participants had 12.1% of serious AE and 24.2% discontinued the treatment due to AE. These differences were not statistically significant ([**Table 3E**](#T3E){ref-type="table"}).

### Immunogenicity {#s4_9_2}

In post-transition stage, frequency of patients with ADA were 10.6% in maintenance group and 12.1% in exchanging group. (p=0.901) ([**Table 3E**](#T3E){ref-type="table"}).

**"Efficacy and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Rheumatoid Arthritis: Comparison between Switching from Reference Infliximab to CT-P13 and Continuing CT-P13 in the PLANETRA Extension Study." Annals of the Rheumatic Diseases 76 (2): 355--63** ([@B68]).

Authors compared two groups of Rheumatoid arthritis patients: maintenance (CTP-13/CTP-13) and exchanging (INF/CTP13). Efficacy, tolerability and safety observed were non different between groups.

### ACR20, ACR50 and ACR70 {#s4_9_3}

Frequencies of 20%, 50% and 70% responses according to the ACR criteria were: 74.1%, 49.4% and 24.7% in CTP-13/CTP-13, and 77.1%, 54.2% and 26.4% in INF/CTP-13 group. There was no evidence of statistically significant differences between groups ([**Table 3A**](#T3A){ref-type="table"}).

### DAS28 {#s4_9_4}

The average final scores were not statistically different between maintenance (2.40) and exchanging (2.48) groups ([**Table 3A**](#T3A){ref-type="table"}).

### EULAR {#s4_9_5}

Frequency of patients with a good or moderate criterion according to EULAR were 80.9% and 81% in maintenance and exchanging arms, respectively. There were no statistical differences between groups (p=0.669) ([**Table 3A**](#T3A){ref-type="table"}).

Safety {#s4_10}
------

### Adverse Events {#s4_10_1}

In maintenance group, 7.5% of patients had serious AE, and 10% discontinued their treatment due to AE. These frequencies did not differ than exchanging group (9% and 5.6%, respectively) ([**Table 3E**](#T3E){ref-type="table"}).

[@B47]. **"Efficacy and Safety of Switching from Reference Infliximab to CT-P13 Compared with Maintenance of CT-P13 in Ankylosing Spondylitis: 102-Week Data from the PLANETAS Extension Study" Annals of the Rheumatic Diseases 76 (2): 346--54** ([@B47]).

This trial was carried out in patients with ankylosing spondylitis. Participants were randomized in two groups: maintenance (CTP-13/CTP-13) and exchanging (INF/CTP-13). No statistically significant differences were observed between group in terms of efficacy or safety.

Efficacy {#s4_11}
--------

### Assessment of Spondylarthritis international Society (ASAS20, ASAS40 and ASAS PR) {#s4_11_1}

Non statistical differences were found between groups according ASAS measurements for 20%, 40% and partial remission of disease: in maintenance (80.7%, 63.9% and 19.3%) and exchanging (76.9%, 61.5% and 23.1%) patients ([**Table 3B**](#T3B){ref-type="table"}).

### Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Metrology Index (BASMI) {#s4_11_2}

Authors reported - using graphical methods - non differences in average at the end of follow-up between maintenance and exchanging groups: BASDAI (3.19 vs. 3.23), BASFI (3.1 vs. 3.25), ASDAS (1.86 vs. 1.97), and BASMI (2.4 vs. 2.6) ([**Table 3B**](#T3B){ref-type="table"}).

Safety {#s4_12}
------

### Adverse Events {#s4_12_1}

In maintenance group, 4.5% and 3.3% of allocated patients had serious AE and discontinued treatment due to AE, respectively. Meanwhile, in exchanging group frequencies were 4.6% in both measures. There are no evidence of statistical differences between arms ([**Table 3E**](#T3E){ref-type="table"}).

### Immunogenicity {#s4_12_2}

In post-exchange period, there were non statistical differences in proportion of patients with ADAs between groups. Authors reported 23.3% in CTP-13/CTP-13 and 27.4% in INF/CTP-13 groups ([**Table 3E**](#T3E){ref-type="table"}).

Preliminary Financial Analysis {#s4_13}
------------------------------

First, we present the estimate of annual costs per patient based on price for each vial offered by each provider, S/2040.00 (S/: Peruvian soles) for BRP and S/857 for BBP; and number of vials required per patient (annual average). This implies annual savings around S/24843 per-patient with biosimilar. Secondly, we estimated the cost differences based on annual requirement of Infliximab from EsSalud (6460 vials); thus, the biosimilar introduction could produce savings around S/7´642,780.00 (1 USD: S/3.30) ([**Table 4**](#T4){ref-type="table"}).

###### 

Preliminary financial analysis about the cost related to treatment with infliximab an its biosimilar in EsSalud (1USD = S/3.30).

  Biological Product    Supplier             Estimation of annual costs per patient   EsSalud Annual Purchase                                               
  --------------------- -------------------- ---------------------------------------- ------------------------- ----------- ---------------- -------------- -----------------
  Infliximab Original   *Johnson& Johnson*   *S/2,040.00*                             *3 vials*                 *7 times*   *S/42,840.00*    *6460 vials*   S/13,178,400.00
  Biosimilar            *AC Farma*           *S/857.00*                                                                     *S/17,997.00*                   S/5,536,220.00
  Difference                                 *-S/1,183.00*                                                                  *-S/24,843.00*                  -S/7,642,780.00

\*Based on what was sold by the suppliers in the last purchase of the biological product registered in the SEACE platform for a vial of infliximab of 100 mg.

\*\*Estimated for 60 kg person on average at a dose of 5mg / kg.

\*\*\*The application is every 8 weeks on average; the annual estimate has been rounded.

\*\*\*\*The total requirement corresponds to what was requested by EsSalud for the year 2018.

Technical Discussion With Medical Doctors {#s4_14}
-----------------------------------------

In first meeting, we received questions and feedback from rheumatologists, dermatologists and gastroenterologists. In second meeting, we discussed those questions an related legal aspects, and we also defined scope and limitations of analysis performed. At the last meeting, we presented and received the approbation of final technical document. The main concerns expressed by doctors were not being able to conclude for each disease separately, nocebo effect and using of generic questionnaires to assess the quality of life. We address them in the discussion.

Discussion {#s5}
==========

Our findings reflect the best primary evidence available related to continuation with a biological biosimilar drug in patients that receive Infliximab -as biological reference drug - in conditions approved by the Peruvian Social Security. While only two of the studies respond directly to PICOS question using Infliximab as original maintenance drug, we included all controlled trials that evaluated interchangeability from the original Infliximab into its biosimilar. All primary studies did not find statistical and clinical differences between maintenance and exchanging groups in efficacy and safety profiles. Moreover, in comparison with infliximab, the use of its biosimilar produce a substantial savings in EsSalud purchasing budget. In addition, both analyzes were discussed and accepted by rheumatologists, dermatologists and gastroenterologists working in EsSalud. In this sense, our manuscript is an integrated technical piece, which embraces scientific evidence, institutional budget and clinical experience about infliximab interchangeability in the complexity of Peruvian Health System, where EsSalud is one of the foremost public institutions with assurance, provision and health care functions ([@B53]; [@B41]). Consequently, we described a mixed methodological approach to inform making-decisions with the best available evidence in low and middle-income countries context.

In the academic realm, other systematic reviews have addressed the interchangeability from original into biosimilar drugs. First, *Chingcuanco* et al., performed a SR in Pubmed, EMBASE, CENTRAL and LILACS until April-2016; they concluded that there is primary evidence that supports interchangeability from Biological reference products to biosimilar drugs in TNF-α family ([@B14]). Second, *Cohen et al*., carried out a SR including interventional and observational clinical studies in MEDLINE and EMBASE until June-2017; in this review the risk of events related to immunogenicity and declination of efficacy did not change after exchanging from original to biosimilar ([@B15]). Third, *McKinnon et al.*, published an SR performed in Pubmed, EMBASE and Cochrane Library until June-2017 to evaluate the efficacy and safety of biosimilar interchangeability. There were still gaps to determining safety and efficacy of interchangeability of biosimilar was their conclusion, although they did not provide any specific conclusion about infliximab ([@B39]). Fourth, *Feagan et. al*, recently published a SR, they searched until January-2018 in Medline for articles and EMBASE for abstract congress. Six RCT and 64 observational studies were included. The authors described that "the evidence revealed no clinically important efficacy or safety signals associated with switching" ([@B23]). Consequently, none of those synthesis studies reported differences in efficacy or safety between maintenance or exchanging into biosimilar, however there are different opinions in recommending the continuation with biosimilar drug.

In technical meetings with specialists, some concerns were exposed. The first was the inability to make specific comparisons for each disease separately- due to low statistical power- specifically in the clinical trial financed by the Government of Norway conducted in patients with rheumatoid arthritis, severe psoriasis, ulcerative colitis, Crohn's disease and spondylarthrosis. ([@B32]). Although the authors performed subgroup analyses for each disease and reported findings with no statistically significant differences for several specific outcomes, their results were exploratory and could be affected by selection bias ([@B3]; [@B12]). However, valid conclusions were obtained for all diseases studied. In this regard, the authors report three main outcomes of efficacy (worsening of the disease, remission of the disease, and quality of life) and two safety outcomes (adverse effects and immunogenicity) for all diseases included. They observed non statistical differences between groups with adequate statistical power. ([@B32]). Therefore, the first two outcomes of efficacy were the total percentage of patients who had worsening or remission of the disease in each group. Definition of state was based on medical evaluation supported by validated and accepted specific clinical scales for each disease ([@B32]).

On the other hand, the use of generic questionnaires to assess quality of life (QoL) across the diseases was the second concern. *Jorgensen* et al. did not find differences in the SF-36 and EQ5D between the maintenance and switched groups ([@B32]). QoL is widely recognized as a valid outcome in clinical studies and as basis for calculating utility measurements ([@B19]; [@B9]). SF-36 and EQ5D can be used in any health conditions; both scales has been used by National Institute of Clinical Excellence (NICE) to assess efficacy of interventions in several diseases, including: rheumatological, dermatological and gastroenterological ([@B37]). It is noteworthy that these two generic indices allow us to estimate utilities measures - as Quality of life adjusted life years (QALY) - for comparing across different health conditions ([@B51]). In the following two paragraphs we provide a succinct description of those tools in relation to diseases evaluated.

The SF-36 is widely used worldwide and it has evidence of validity and reliability in Peru ([@B52]). A series of SR show that this tool has adequate psychometric properties in patients with RA ([@B38]), it allows to quantify worsening psoriasis in clinical trials ([@B2]) and it is a valid outcome in patients with psoriatic arthritis that receive biological drugs ([@B20]). In addition, for inflammatory bowel disease, SR described that SF-36 is useful to assess the quality of life and it provides evidence of variations in stages of activity and inactivity of the disease ([@B33]) and a Cochrane systematic review describe that SF-36 is a valid and reliable instrument to evaluate the effect of biological therapy. ([@B35]). Moreover, other SRs argue that this questionnaire has psychometric validity ([@B66]) and serves to estimate the burden of disease in patients with ulcerative colitis ([@B67]). Also, SF-36 is useful to assess QoL in patients with ankylosing spondylitis ([@B65]).

The EQ5D is a tool developed by EUROQOL that, with appropriate contextualization, serves as the basis for the calculation of QALYs ([@B11]; [@B17]). There is a Peruvian version of EQ5D ([@B58]; [@B13]). In patients with rheumatoid arthritis its use has been described in the estimation of utility measures ([@B10]), clinical practice ([@B30]), also it has a good correlation with disease activity ([@B56]). EQ-5D is a valid and reliable instrument in the assessment of worsening in clinical trials conducted in patients with psoriasis. ([@B2]). Also, it is used in patients with plaque psoriasis, psoriatic arthritis ([@B37]; [@B65]) and multicenter studies of skin diseases ([@B5]). A Cochrane SR described that EQ-5D was adequate in the evaluation of the effectiveness of treatment with biological drugs in patients with inflammatory bowel disease ([@B35]). Likewise, EQ-5D is an adequate tool to measure quality of life in ankylosing spondylitis patients ([@B8]) and high correlation with specific scales of the disease has been observed ([@B43]).

Similarly, safety is a highly important outcome studied. We defined immunogenicity and adverse events as main safety results. Immunogenicity is a relevant marker in the biotherapeutics research, since the production of anti-drug antibodies is clearly associated with therapeutic failure and side effects of protein drugs ([@B31]). Also, immunogenicity of Infliximab biosimilar can be extrapolated to the different diseases treated ([@B6]). Moreover, the adverse events, especially the serious ones, are valid safety outcomes for a biological drug in the context of clinical trials ([@B60]). Subsequently, we incorporated two main safety measures in the biosimilars arena.

Our study has potential limitations. First, we did not include unpublished studies from the gray literature (reports, conference proceedings, doctoral theses/dissertations, etc.), which may imply a selection bias. But, critical appraisal of the evidence is essential for developing a SR, since, although the findings can be made known, we cannot evaluate their quality, which has repercussions on the validity and reliability of a synthesis study ([@B7]). Second, non-inclusion of observational studies could be a selection bias source, even more when the academy recognizes them as a valid source of clinical evidence ([@B27]; [@B16]). Nevertheless, our manuscript is circumscribed in a specific decision-making environment, where there is an institutional regulatory framework. In EsSalud, IETSI has defined that-- based on internal validity criterion- randomized clinical trials are the main source of evidence to inform making-decisions; in addition, the overall results of SRs - that included observational studies - did not differ from RCT findings and provide consistency to our results. Third, we did not carry out a quantitative synthesis of the studies, due to the enormous clinical and methodological heterogeneity, but in this situation performing meta-analysis is not advisable ([@B40]). Fourth, we have not considered drop-out rates and nocebo effect, which could potentially exist in switched patients (from original into biosimilar) ([@B34]; [@B46]); education provided prior to switch -among other interventions - is a valuable tool that can greatly help overcome this effect ([@B50]). Fifth, in the financial analysis, we do not have the official information of short-term patients and long-term chronic patients in each disease approved; however, our estimation is valid since it was based on absolute institutional annual requirement of infliximab. Sixth, we did not have a national representative sample of physicians; however, participants were working in the main healthcare networks of EsSalud.

Beyond the limitations and based on cost-opportunity as a legitimate principle of collective health, our findings support the use of a biosimilar to continue the treatment in patients receiving infliximab in EsSalud. Therefore, biosimilar constitute a valid therapeutic alternative for the management of medical conditions approved in EsSalud. Access to biological drugs is a struggle for health care systems, especially in low and middle-income economies, where a key aspect is the price of these innovative medicines, which leads to a significant economic exertion from Governments and their public budgets. In this sense, infliximab biosimilars are an alternative that could be efficient in the Peruvian Social Security context.
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